bioMérieux Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Pierre Boulud

Chief executive officer

€2.5m

Total compensation

CEO salary percentage25.7%
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.9yrs
Board average tenure9.6yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Pierre Boulud's remuneration changed compared to bioMérieux's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023€2m€631k

€358m

Sep 30 2023n/an/a

€372m

Jun 30 2023n/an/a

€386m

Mar 31 2023n/an/a

€419m

Dec 31 2022€2m€510k

€452m

Sep 30 2022n/an/a

€502m

Jun 30 2022n/an/a

€552m

Mar 31 2022n/an/a

€577m

Dec 31 2021€2m€510k

€601m

Sep 30 2021n/an/a

€555m

Jun 30 2021n/an/a

€509m

Mar 31 2021n/an/a

€457m

Dec 31 2020€1m€497k

€404m

Compensation vs Market: Pierre's total compensation ($USD2.62M) is below average for companies of similar size in the UK market ($USD5.70M).

Compensation vs Earnings: Pierre's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Pierre Boulud (53 yo)

less than a year

Tenure

€2,452,864

Compensation

Mr. Pierre Boulud is Chief Executive Officer of bioMérieux S.A. from July 01, 2023. He served as Chief Operating Officer of Clinical Operations at BioMérieux S.A. until 2023 and served as its Chief Operati...


Leadership Team

NamePositionTenureCompensationOwnership
Pierre Boulud
Chief Executive Officerless than a year€2.45mno data
Guillaume Bouhours
Executive VP of Purchasing and Information Systems & CFO6.3yrsno datano data
Sylvain Morgeau
Investor Relationsno datano datano data
Audrey Dauvet
Executive Vice President of Legal1.4yrsno datano data
Valerie Leylde
Executive Vice President of Human Resources5.4yrsno datano data
Pierre Charbonnier
Executive Vice President of Global Quality6.3yrsno datano data
Yasha Mitrotti
Executive Vice President of Industrial Applications6.3yrsno datano data
Frederic Beseme
Head of CSR4.4yrs€21.99k0%
€ 0
Jennifer Zinn
Executive Vice President of Clinical Operationsless than a yearno datano data
Charles Cooper
Executive VP & Chief Medical Officerless than a yearno datano data
Celine Roger-Dalbert
Executive Vice President of Research & Developmentless than a yearno datano data
Franck Admant
Director of Investor Relationsno datano datano data

2.9yrs

Average Tenure

51.5yo

Average Age

Experienced Management: BIMP's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alain Merieux
Founding Chairman6.8yrsno datano data
Jean-Luc Belingard
Non-Independent Director17.8yrs€52.00k0.051%
€ 5.3m
Philippe Archinard
Non-Independent Director14yrs€61.00k0.000030%
€ 3.1k
Alexandre Merieux
Chairman20.2yrs€1.92m0.000050%
€ 5.2k
Harold Y. Boel
Independent Director12.1yrs€56.00k0.00013%
€ 13.6k
Marie-Helene Habert-Dassault
Independent Director12.1yrs€44.00k0.000050%
€ 5.2k
Fanny Letier
Independent Director7.1yrs€61.17k0.000030%
€ 3.1k
Viviane Monges
Independent Directorless than a yearno datano data
Marie-Paule Kieny
Independent Director6.8yrs€35.00k0.00015%
€ 15.7k
Sylvain Orenga
Employee Representative Director2.1yrs€52.00kno data

9.6yrs

Average Tenure

60.5yo

Average Age

Experienced Board: BIMP's board of directors are considered experienced (9.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.